FOLH1 and neoplasm: Taken together, these observations suggest that PSA is a sufficiently reliable and easily determinable surrogate parameter for the early prediction of response to PSMA-RLT, despite the fact that neither PSA decline nor tumor shrinkage are formally hard, FDA-relevant parameters for drug approval [7].